biostudies-literatureSalazar-Puerta AINIBIB NIH HHSNIDDK NIH HHSNIHNIAMS NIH HHS309-324https://www.ebi.ac.uk/biostudies/studies/S-EPMC10550890biostudies-literatureUnknown16(4)<h4>Introduction</h4>Valvular heart disease represents a significant burden to the healthcare system, with approximately 5 million cases diagnosed annually in the US. Among these cases, calcific aortic stenosis (CAS) stands out as the most prevalent form of valvular heart disease in the aging population.  CAS is characterized by the progressive calcification of the aortic valve leaflets, leading to valve stiffening. While aortic valve replacement is the standard of care for CAS patients, the long-term durability of prosthetic devices is poor, calling for innovative strategies to halt  or reverse disease progression. Here, we explor the potential use of novel extracellular vesicle (EV)-based nanocarriers for delivering molecular payloads to the affected valve tissue. This approach aims to rCellular and molecular bioengineeringEngineered Extracellular Vesicle-Based Therapies for Valvular Heart Disease.PMC10550890DP1 DK126199R01AR079485R01 AR079485DP2 EB028110DP2EB028110DP1DK126199Rincon-Benavides MADasi LPBlackstone BNCuellar-Gaviria TZSalazar-Puerta AIHiguita-Castro NFlemister DBarringer GDeng BPowell HKordowski MGuilfoyle EHussein JGallego-Perez DMayoral-Andrade GMcComb DWZepeda-Orozco DfalseEngineered Extracellular Vesicle-Based Therapies for Valvular Heart Disease.<h4>Introduction</h4>Valvular heart disease represents a significant burden to the healthcare system, with approximately 5 million cases diagnosed annually in the US. Among these cases, calcific aortic stenosis (CAS) stands out as the most prevalent form of valvular heart disease in the aging population.  CAS is characterized by the progressive calcification of the aortic valve leaflets, leading to valve stiffening. While aortic valve replacement is the standard of care for CAS patients, the long-term durability of prosthetic devices is poor, calling for innovative strategies to halt  or reverse disease progression. Here, we explor the potential use of novel extracellular vesicle (EV)-based nanocarriers for delivering molecular payloads to the affected valve tissue. This approach aims to r2023-01-01T00:00:00Z2023 Aug2026-07-14T20:43:08.421Z2025-04-06T22:39:17.281ZS-EPMC105508903781099710.1007/s12195-023-00783-x